Melton Tyler C, Ryan MaryKathleen, Stallings Andrew M, Park Sang H, Lanier Cameron, Ballou Jordan Marie, Rosenthal Meagen
University of Tennessee Health Science Center College of Pharmacy, Department of Clinical Pharmacy and Translational Science, United States of America.
Ballad Health at Johnson City Medical Center, United States of America.
Explor Res Clin Soc Pharm. 2025 Mar 25;18:100595. doi: 10.1016/j.rcsop.2025.100595. eCollection 2025 Jun.
Pharmacy Benefit Managers (PBMs) are responsible for establishing community pharmacy reimbursement practices and prices to varying degrees. Understanding PBMs' reimbursement practices is necessary for the continued viability of community pharmacies located in underserved and rural patient communities. Currently, there is a gap in literature exploring PBM reform and the impact this legislation has on rural pharmacy practice.
This content analysis reviews the legislation complied by the National Community Pharmacists Association (NCPA) and determines its benefits to pharmacies and patients in rural areas.
The NCPA PBM Reform legislation document included bills from 48 states and the District of Columbia, that were introduced between November 30, 2018, through December 7, 2021. Bills were classified as enacted ( = 81), in debate ( = 186), or as having failed to be enacted ( = 120). Eighty-one enacted bills were reviewed to assess if it benefited patients, pharmacies, or both. Bills not benefiting either pharmacies or patients were excluded.
Fifty-seven bills were included in the content analysis, where six categories were identified using thematic analysis and classified as: PBM Operations, Drug Pricing, Transparency, Reimbursements, Cost Sharing, and Prior Authorization. Only twenty-two bills were identified as potentially benefitting both rural pharmacies and rural patients through inclusion of legislation managing PBM practices involving patient steering, network adequacy, pricing transparency, reforming cost-sharing structures, and streamlining prior authorization processes.
This study identifies multiple PBM legislation categories having the potential to impact rural pharmacy operations and patient outcomes. However, further research is needed to understand the specific financial and clinical impact of these PBM legislation categories on rural communities and rural pharmacy practice, as well as their alignment with enabling pharmacists to combat unique health disparities and challenges facing rural communities.
药品福利管理机构(PBMs)在不同程度上负责制定社区药房的报销政策和价格。了解PBMs的报销政策对于服务欠缺地区和农村患者社区的社区药房的持续生存能力至关重要。目前,在探索PBM改革及其立法对农村药房实践的影响方面,文献存在空白。
本内容分析回顾了美国全国社区药剂师协会(NCPA)整理的立法,并确定其对农村地区药房和患者的益处。
NCPA的PBM改革立法文件包括2018年11月30日至2021年12月7日期间提出的来自48个州和哥伦比亚特区的法案。法案被分类为已颁布(=81)、在辩论中(=186)或未颁布(=120)。对81项已颁布的法案进行审查,以评估其是否使患者、药房或两者受益。未使药房或患者受益 的法案被排除。
57项法案纳入内容分析,通过主题分析确定了六个类别,分类为:PBM运营、药品定价、透明度、报销、费用分摊和预先授权。只有22项法案被确定可能通过纳入管理PBM实践的立法使农村药房和农村患者都受益,这些实践涉及患者引导、网络充足性、定价透明度、改革费用分摊结构以及简化预先授权流程。
本研究确定了多个可能影响农村药房运营和患者结局的PBM立法类别。然而,需要进一步研究以了解这些PBM立法类别对农村社区和农村药房实践的具体财务和临床影响,以及它们与使药剂师能够应对农村社区面临的独特健康差异和挑战的一致性。